Infused Drugs - Global Strategic Business Report

The global market for Infused Drugs was valued at US$8.2 Billion in 2024 and is projected to reach US$11.8 Billion by 2030, growing at a CAGR of 6.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Infused Drugs market.

Global Infused Drugs Market - Key Trends & Drivers Summarized

Why Are Infused Drugs Gaining Preference Across Therapeutic Areas?

Infused drugs, administered directly into the bloodstream or tissue via intravenous or subcutaneous routes, are essential in managing conditions that require rapid, precise, or long-duration dosing. These drugs are widely used in oncology, autoimmune diseases, rare disorders, and chronic infections where oral or topical treatments are inadequate. Infusion allows for controlled bioavailability and bypasses issues related to poor gastrointestinal absorption or patient non-compliance.

Advances in biologics and targeted therapies have expanded the role of infused drugs in treating conditions such as rheumatoid arthritis, multiple sclerosis, and cancer. Infused monoclonal antibodies, immunotherapies, and enzyme replacement therapies are providing highly specific, disease-modifying treatment options. As personalized medicine becomes more prevalent, infused drugs are being tailored based on genetic and biomarker profiles, improving therapeutic precision and outcomes in complex disease areas.

How Are Delivery Systems and Care Settings Evolving?

The administration of infused drugs is shifting beyond hospitals to outpatient clinics, home care, and specialized infusion centers. Portable infusion pumps and simplified infusion kits are enabling greater flexibility and comfort for patients requiring long-term treatment. Home infusion services are expanding, particularly for chronic conditions that need recurrent dosing, supported by remote monitoring and nurse-assisted administration.

Drug delivery systems are also advancing with smart pumps, closed-system transfer devices, and formulations that allow extended infusion intervals. These innovations reduce infection risks, increase patient safety, and improve adherence. Biosimilar versions of infused biologics are being introduced to reduce treatment costs and improve access in both high-income and emerging markets. Formulation technologies are also being optimized to shorten infusion times and reduce infusion-related reactions.

Where Is Market Demand Increasing, and Who Are the Main End-Users?

Oncology remains the largest segment for infused drugs, accounting for a substantial share of global demand due to the rise in cancer incidence and expanded use of targeted therapies. Autoimmune diseases such as Crohn’s disease, psoriasis, and systemic lupus are also major contributors to infusion drug usage. Hospital pharmacies, outpatient infusion clinics, and specialty care centers are the primary settings for administration.

Demand is increasing in both developed and developing countries. North America leads in utilization due to the presence of specialized treatment facilities and reimbursement frameworks. Europe follows with strong adoption of biosimilars and home-based infusion models. Asia Pacific is experiencing growth due to rising healthcare access, cancer screening programs, and government-backed chronic care initiatives. Infusion drug demand is also supported by transplant care, infectious disease management, and rare metabolic disorders.

What Is Driving Growth in the Infused Drugs Market?

Growth in the infused drugs market is driven by several factors including increasing incidence of chronic and rare diseases, advances in biologic therapies, and rising adoption of outpatient and home-based infusion services. Technological improvements in delivery systems, including portable and programmable infusion devices, are supporting safer and more convenient treatment settings. Demand is also supported by expanding indications for infused immunotherapies and long-acting biologics across autoimmune and oncology domains.

End-use expansion in ambulatory care, specialty clinics, and home infusion programs is increasing treatment accessibility while reducing the cost burden of inpatient administration. Development of biosimilars and payer initiatives to support home infusions are creating cost-effective treatment pathways. The growing role of precision medicine and companion diagnostics is strengthening demand for high-efficacy infused drugs with targeted mechanisms of action. These trends are collectively reinforcing the global market for infused therapies across multiple disease areas and care models.

Scope of the Report

The report analyzes the Infused Drugs market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below:

• Segments: Drug Type (Small Molecules Drug, Biologics Drug); Therapeutic Area (Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Diabetes Therapeutic Area, Other Therapeutic Areas).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Small Molecules Drug segment, which is expected to reach US$7.6 Billion by 2030 with a CAGR of a 7.5%. The Biologics Drug segment is also set to grow at 4.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $2.2 Billion in 2024, and China, forecasted to grow at an impressive 10.0% CAGR to reach $2.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Infused Drugs Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Infused Drugs Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Infused Drugs Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Apotex Inc., AstraZeneca plc and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 36 companies featured in this Infused Drugs market report include:

• AbbVie Inc.
• Amgen Inc.
• Amneal Pharmaceuticals Inc.
• Apotex Inc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Eli Lilly and Company
• Endo International plc
• Hikma Pharmaceuticals plc
• Parenteral Drugs (India) Ltd.
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Stada Arzneimittel AG
• Teva Pharmaceutical Industries Ltd.
• Weefsel Pharma (Weefsel Biopharma)
• Wockhardt Ltd.
• Zydus Cadila

This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis from 2015 to 2023.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025 (E), competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.